A Japanese flu drug has proven to be effective in treating the coronavirus in early trials, according to reports on Wednesday.
Medical authorities in China said they tested the antiviral drug favipiravir on 340 patients and found it reduces recovery time and improves lung condition of patients, according to the Guardian.
Zhang Xinmin, director of China’s National Center for Biotechnology Development, said the favipiravir drug had produced positive outcomes during clinical trials in Wuhan and Shenzen. The report on Tuesday said 340 patients had taken part in the clinical trials.
“It has a high degree of safety and is clearly effective in treatment,” Zhang told reporters.
Patients treated with the drug, which was developed by a subsidiary of Fujifilm, in Shenzen were found to turn negative for Covid-19 after a median of four days, rather than 11 days for those who were not treated with favipiravir, the outlet reported, citing public broadcaster NHK.
As of Wednesday, more than 200,000 people worldwide were reported to have contracted the coronavirus, according to data compiled by Johns Hopkins University, with over 9,000 deaths.
The WHO has recognized the coronavirus outbreak as a pandemic.



